Literature DB >> 16542379

Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Raffaele De Palma1, Francesco Del Galdo, Salvatore Lupoli, Paolo Altucci, Gianfranco Abbate, Gabriele Valentini.   

Abstract

In recent years several reports have suggested that T cells may have a role in systemic sclerosis (SSc). The aim of our study was to investigate the dynamics of T cell repertoire in early SSc disease analysing a target organ, the skin, and the peripheral blood. To date, indeed, it is not clear if T cell expansions found in SSc reflect a general activation or result from specific antigen stimulation in the target organs. This is an important point to assess in order to characterize the role of T cells in the development of SSc. To address these questions we studied T cell repertoire by CDR3 length analysis in skin biopsies and peripheral blood obtained from patients affected by SSc and we found that a skewed T cell repertoire was present only in the biopsies. In order to characterize more effectively the meaning of these data, we performed co-cultures using fibroblasts and peripheral blood mononuclear cells (PBMCs) obtained from SSc patients. These experiments showed that same T cell expansions were detectable in the skin of SSc patients and in the cultures of PBMCs and autologous fibroblasts of the patients but not in their peripheral blood. Taken together, these data suggest that fibroblasts trigger specific T cell expansions in the early phase of SSc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542379      PMCID: PMC1809638          DOI: 10.1111/j.1365-2249.2006.03041.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  T cell receptor V beta repertoire of double-negative alpha/beta T cells in patients with systemic sclerosis.

Authors:  A Sakamoto; T Sumida; T Maeda; M Itoh; T Asai; H Takahashi; S Yoshida; T Koike; H Tomioka; S Yoshida
Journal:  Arthritis Rheum       Date:  1992-08

Review 2.  Is systemic sclerosis an antigen-driven T cell disease?

Authors:  Lazaros I Sakkas; Chris D Platsoucas
Journal:  Arthritis Rheum       Date:  2004-06

3.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

4.  Cellular infiltrates in scleroderma skin.

Authors:  R Fleischmajer; J S Perlish; J R Reeves
Journal:  Arthritis Rheum       Date:  1977-05

5.  A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon.

Authors:  A Gabrielli; M Montroni; S Rupoli; M L Caniglia; F DeLustro; G Danieli
Journal:  Arthritis Rheum       Date:  1988-11

6.  Expression and function of surface antigens on scleroderma fibroblasts.

Authors:  D Abraham; S Lupoli; A McWhirter; C Plater-Zyberk; T H Piela; J H Korn; I Olsen; C Black
Journal:  Arthritis Rheum       Date:  1991-09

7.  Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents.

Authors:  C Fertin; J F Nicolas; P Gillery; B Kalis; J Banchereau; F X Maquart
Journal:  Cell Mol Biol       Date:  1991       Impact factor: 1.770

8.  Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts.

Authors:  J Varga; J Rosenbloom; S A Jimenez
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

9.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis.

Authors:  M Ferrarini; V Steen; T A Medsger; T L Whiteside
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

View more
  7 in total

1.  Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.

Authors:  E Favoino; I E Favia; S Vettori; C Vicenti; M Prete; G Valentini; F Perosa
Journal:  Clin Exp Immunol       Date:  2015-05-10       Impact factor: 4.330

Review 2.  A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases.

Authors:  Radjesh Bisoendial; Erik Lubberts
Journal:  Mediators Inflamm       Date:  2022-05-17       Impact factor: 4.529

Review 3.  Autoimmunity in systemic sclerosis: current concepts.

Authors:  Francesco Boin; Antony Rosen
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

4.  Apoptosis modulation as a promising target for treatment of systemic sclerosis.

Authors:  Stéphane Chabaud; Véronique J Moulin
Journal:  Int J Rheumatol       Date:  2011-09-06

5.  DNA methylation patterns in juvenile systemic sclerosis and localized scleroderma.

Authors:  Patrick Coit; Kaila L Schollaert; Emily M Mirizio; Kathryn S Torok; Amr H Sawalha
Journal:  Clin Immunol       Date:  2021-05-13       Impact factor: 10.190

6.  Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.

Authors:  Elvira Favoino; Liboria Digiglio; Giovanna Cuomo; Isabella E Favia; Vito Racanelli; Gabriele Valentini; Federico Perosa
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

7.  T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis.

Authors:  Serena Vettori; Giusi Barra; Barbara Russo; Alessia Borgia; Giuseppe Pasquale; Luciana Pellecchia; Lucia Vicedomini; Raffaele De Palma
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.